Amniotics (AMNI.ST) Stock Analysis & AI Equity Report
Amniotics (AMNI.ST) overview
Amniotics (AMNI.ST) stock analysis and AI equity research. For the latest completed financial year, 2023, Amniotics reported revenue of SEK 0m and operating profit of SEK -29.1m; the year-end share price was 0.01 SEK and market capitalisation was SEK 25.3m. Amniotics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Amniotics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-08-30. Data will be refreshed during report generation.
About Amniotics
Amniotics AB was a clinical-stage biotechnology company focused on stem-cell-based therapies derived from amniotic fluid. It developed candidate treatments for diseases with unmet medical needs and operated a GMP manufacturing facility approved by Swedish regulators, including CDMO services for other biotech companies. In 2024, it merged into Magle Group and was dissolved.
Generate the Amniotics report
Amniotics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Amniotics and represent the latest completed financial year (2023). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.